EASTONBIOPHARMACEUTICALS(688513)2025-02-27 07:50Financial Performance - Total revenue for 2024 reached CNY 134,830.15 million, representing a year-on-year increase of 20.69%[5] - Net profit attributable to shareholders of the parent company was CNY 23,656.53 million, up 4.41% compared to the previous year[5] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 10.84% to CNY 17,466.48 million[5] - Basic earnings per share rose to CNY 1.36, reflecting a growth of 6.25%[3] Assets and Equity - Total assets at the end of the reporting period were CNY 343,281.04 million, a 2.57% increase from the beginning of the period[5] - Shareholders' equity attributable to the parent company increased by 3.57% to CNY 269,625.57 million[5] - The significant increase in share capital and net asset per share was due to a capital reserve conversion of 4.7 shares for every 10 shares held[6] Employee Incentives - The company implemented a three-year employee stock ownership plan and recognized stock incentive expenses of CNY 20.12 million during the reporting period[5] Market Expansion - The company plans to continue expanding its raw material drug market and has seen stable growth in domestic and international sales[5] Financial Data Disclaimer - Investors are advised to note that the financial data is preliminary and subject to change upon final audit[7]